<sup>68</sup>Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy
Helena Lanzafame(Essen University Hospital), Wolfgang P. Fendler(Essen University Hospital), Sebastian Bauer(Science for Life Laboratory), Martin Schüler(German Cancer Research Center), Michael A. Nader(Wake Forest University), Kim M. Pabst(West German Heart and Vascular Center Essen), Mélanie Desaulniers(Université de Sherbrooke), Jens T. Siveke(German Cancer Research Center), Nader Hirmas(German Breast group), Rainer Hamacher(Essen University Hospital), Ilektra A. Mavroeidi(German Cancer Research Center), Francesco Barbato(Deutsches Konsortium für Translationale Krebsforschung), Ken Herrmann(Essen University Hospital), Stephan Leyser(Düsseldorf University Hospital), Marc Ingenwerth(Deutschen Konsortium für Translationale Krebsforschung), Timo Bartel(Essen University Hospital), Lukas Kessler(Düsseldorf University Hospital)
Cited by 36
Related Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k